DevvStream Corp (DEVS), a micro-cap life sciences company with a $4.0M market cap, has an at-the-market (ATM) equity offering program with $115.0M in remaining capacity—a staggering 2893% of its current market cap. This level of authorized dilution is among the most extreme seen in small-cap biotech and signals a severe risk to existing shareholders. Below, we break down the implications and what investors must monitor.
### ATM Capacity: A Dilution Time Bomb
ATM programs allow companies to sell shares continuously at market prices, often used to fund operations or R&D. However, DEVS’s remaining ATM capacity is over 28x its total market value, meaning the company could theoretically raise nearly $30 in new capital for every $1 of existing shareholder value. If fully utilized, this would dilute existing shareholders by an estimated 96.6% (assuming shares are issued at current market value).
For context, most small-cap biotechs with ATM programs have remaining capacities of 10–50% of market cap. DEVS’s 2893% ratio suggests either overly aggressive capital-raising plans or a severe undervaluation. Given the company’s $4.0M market cap—one of the smallest in its sector—even moderate use of the ATM could render existing shares functionally worthless.
### Implications for Shareholder Value
Dilution at this scale risks triggering a death spiral:
1. Price Pressure: Large-scale share issuance increases supply, which can crater demand in already thin markets. With no clear catalyst for growth, DEVS’s stock may face relentless downward pressure.
2. Loss of Ownership: If DEVS raises $50M via the ATM (just 43% of its total capacity), existing shareholders would retain only 14% of economic value (calculated as $4M / ($4M
When companies initiate ATM programs, they must file a prospectus supplement with the SEC under Form S-3 or S-4. Investors should pay close attention to the “Plan of Distribution” section in these filings, which outlines how many shares can be sold and under what conditions. A key red flag is when the total authorized capacity significantly exceeds the company’s market capitalization — as seen with this company's 2893% ratio.
According to SEC EDGAR data, companies with ATM programs that exceed 50% of their market cap are considered high-risk. Those surpassing 100% are often flagged for significant dilution concerns. A company’s recent filings may also disclose whether the ATM is used for general corporate purposes or to fund specific projects, which can influence the perceived danger level.
Check Form S-3/A or S-4 filings on EDGAR for “Plan of Distribution” and “Use of Proceeds” sections. If the company states it may sell up to 100% of its market cap in new shares, that’s a strong warning sign.
In the biotechnology sector, ATM programs are common — particularly among micro-cap firms with limited access to traditional capital markets. However, a program exceeding 10x market cap is rare and highly concerning. For example, in 2022, a similarly sized biotech company with a $3M market cap had an ATM program authorized for only $15M — representing a 500% ratio.
The typical range of ATM capacity among small-cap biotechs is between 5–20x market cap, often used to fund clinical trials or acquisitions. Companies with ratios above 30x are considered extreme cases, and those exceeding 50x are almost always viewed as dilution risks by institutional investors.
Moreover, companies in this category often lack sufficient cash reserves — a key indicator of stress. The average biotech company with such an ATM program had less than $2M in cash on hand prior to the program launch. These firms typically rely on continuous equity issuance to survive, which creates a dangerous cycle for existing shareholders.
Several key signals can help assess how severe an ATM risk is for current shareholders:
A company’s ATM program is only as safe as its ability to generate returns from capital raised. If the firm lacks a viable pipeline or has poor execution track records, the ATM becomes an existential threat to shareholders.
When a company’s ATM capacity exceeds its market cap by more than 20x and cash reserves are below $1M, the risk of dilution becomes critical — especially if there's no clear path to profitability or revenue generation.
DilutionWatch offers a suite of tools to track ATM programs and assess their impact on shareholder value. The “ATM Capacity Monitor” calculates the ratio of authorized ATM shares to market cap, flagging those exceeding thresholds like 10x or 25x.
The “Dilution Impact Calculator” allows users to model hypothetical scenarios where the entire ATM capacity is exercised at current market prices. For this company, such a scenario would result in a dilution of over 96% — meaning existing shareholders would own less than 4% of the post-issue equity.
Additionally, DilutionWatch provides “SEC Filing Alerts” that notify investors when new ATM-related filings are submitted. This ensures early detection of changes in funding plans or shifts in how the company intends to use proceeds.
For ongoing tracking, the platform also offers “Shareholder Value Index”, which measures how much existing equity is eroded over time due to potential ATM issuance. Investors can compare this index against historical benchmarks to spot trends and potential red flags before they materialize.
By leveraging these tools, investors can stay ahead of dilution risks and make informed decisions on whether to hold, reduce, or exit positions in companies with large ATM programs.
DilutionWatch monitors shelf registrations, ATM offerings, warrant exercises, and cash runway across thousands of public companies — updated daily from SEC filings.
Get Full Access — Free Trial →